OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 125,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock in a transaction that occurred on Tuesday, April 8th. The stock was purchased at an average cost of $1.48 per share, for a total transaction of $185,000.00. Following the acquisition, the chief executive officer now owns 213,876,448 shares of the company’s stock, valued at $316,537,143.04. This represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, April 1st, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.65 per share, with a total value of $165,000.00.
• On Friday, March 28th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.70 per share, for a total transaction of $255,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.74 per share, for a total transaction of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The shares were bought at an average cost of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The stock was purchased at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The stock was bought at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.46 on Wednesday. The company has a market cap of $980.46 million, a P/E ratio of -7.68 and a beta of 1.78. The business has a fifty day simple moving average of $1.69 and a 200-day simple moving average of $1.58. OPKO Health, Inc. has a 52 week low of $1.15 and a 52 week high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

OPK has been the subject of several research reports. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Monday. Finally, Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Millennium Management LLC grew its position in shares of OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Northern Trust Corp increased its position in shares of OPKO Health by 4.7% in the 4th quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock worth $5,436,000 after purchasing an additional 164,847 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after purchasing an additional 949,671 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of OPKO Health by 42.3% during the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after purchasing an additional 425,484 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.